CIK 0001600620
- Large accelerated filer
Aurinia Pharmaceuticals Inc.
Sign in to watch- Ticker
- AUPH
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Entity type
- Operating
- EIN
- 981231763
- Phone
- +1 250-744-2487
- Business address
- #140, 14315 - 118 AVENUE, EDMONTON, Alberta, Canada, T5L 4S6
- 3 Insider Initial Statement of Ownership
- 4 Derivatives Options or other derivatives
- 3 Insider Initial Statement of Ownership
- 4 Derivatives Options or other derivatives
- 3 Insider Initial Statement of Ownership
- 4 Grant or award Director acquired 9,310 shares (grant or award)
- 4 Open-market sale Director sold 8,733 shares at $11.26 ($98,334)
- 4 Open-market sale Director sold 272 shares at $10.58 ($2,878)
- 4 Open-market sale Director sold 4,650 shares at $11.26 ($52,359)
- 4 Exercise or conversion Director acquired 8,733 shares (option exercise)
- 4 Open-market sale Director sold 4,818 shares at $11.26 ($54,251)
- 4 Open-market sale Director sold 4,815 shares at $11.26 ($54,217)
- 4 Open-market buy Director bought 20,000 shares at $8.91 ($178,284)
- 4 Grant or award EVP, Ops & Strategy acquired 271,134 shares (grant or award)
- 4 Open-market sale Chief Financial Officer sold 11,296 shares at $8.94 ($100,986)
- 4 Open-market sale EVP, General Counsel sold 19,402 shares at $8.94 ($173,454)
- 4 Grant or award Chief Business Officer acquired 107,202 shares (grant or award)
- 4 Grant or award Chief Commercial Officer acquired 170,188 shares (grant or award)
- 4 Grant or award EVP, Research and Development acquired 191,462 shares (grant or award)
- 4 Open-market sale Chief Executive Officer sold 32,750 shares at $8.94 ($292,785)
Page 5 of 10 · 184 filings